India, Jan. 29 -- Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company, shares climbed above 30% in the overnight trade after announcing that the U.S. Food and Drug Administration FDA has cleared its Investigational New Drug (IND) application for SER-252, its therapy for advanced Parkinson's disease after a clinical hold since November.
The IND clearance will enable Serina to proceed with regulatory and site-level activities for the initiation of Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson's disease.
SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation or CDS that has been shown...